---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-013987"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T01:45:16.040041+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCardia announces first patient enrolled in Phase 3 CardiAMP HF II heart failure trial

## Summary
- First patient enrolled in Phase 3 randomized, double-blind, placebo-controlled CardiAMP HF II trial at BayCare Morton Plant Hospital in Clearwater, Florida.
- 250-patient multicenter study targeting ischemic HFrEF patients with elevated NTproBNP; composite primary endpoint includes death, nonfatal MACE, and quality of life.
- Company preparing regulatory submissions in Japan and the USA based on prior CardiAMP HF, TAC-HFT, and TABMMI trial data.
- Advances include cell population analysis at screening to define treatment doses and use of FDA-approved Morph DNA steerable catheter.

## SEC filing metadata
- accession: 0001437749-25-013987
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925013987/0001437749-25-013987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925013987/bcda20250501_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-013987
- JSON: https://secwatch.observer/filing/0001437749-25-013987.json
- Plain text: https://secwatch.observer/filing/0001437749-25-013987.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.